A Phase I Trial of Ipilimumab (Anti CTLA- 4 Antibody) in Combination With Lenalidomide (IMiD) in Patients With Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Ipilimumab (Primary) ; Lenalidomide
- Indications Cancer
- Focus Adverse reactions
- 07 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 10 Jun 2017 Biomarkers information updated
- 07 Jul 2016 Status changed from recruiting to active, no longer recruiting.